Niklas Klümper

17PUBLICATIONS
110CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer diagnosisNgā mātauranga taiao o te Māori (Māori environmental knowledges)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Sep 09, 2026
Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma.

|Jun 13, 2025
The Antibody-Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma.

Racha Hosni, Niklas Klümper, Christine Sanders

|Dec 16, 2024
C-Reactive Protein Facilitates Premetastatic Niche Formation in the Lungs.

Jonas Saal, Niklas Klümper, Michael Hölzel

|Apr 24, 2024
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.

Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz

|Feb 10, 2024
Feasibility of Monitoring Response to Metastatic Prostate Cancer Treatment with a Methylation-Based Circulating Tumor DNA Approach.

Thomas Büttner, Dimo Dietrich, Romina Zarbl

|Jan 04, 2024
Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.

Sana Hosni, Viola Kilian, Niklas Klümper

Pageof 3

Frequent Collaborators

10 joint publications

Jörg Ellinger

8 joint publications

Michael Hölzel

7 joint publications

Marieta Toma

6 joint publications

Markus Eckstein